| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
|
J Clin Oncol
|
2010
|
9.86
|
|
2
|
Androgen deprivation therapy for prostate cancer.
|
JAMA
|
2005
|
6.07
|
|
3
|
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
|
J Clin Oncol
|
2004
|
3.16
|
|
4
|
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
|
J Clin Oncol
|
2004
|
3.11
|
|
5
|
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
|
Lancet Oncol
|
2012
|
2.51
|
|
6
|
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
|
Clin Cancer Res
|
2010
|
2.45
|
|
7
|
Cancer vaccines: moving beyond current paradigms.
|
Clin Cancer Res
|
2007
|
2.40
|
|
8
|
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
|
Clin Cancer Res
|
2007
|
2.24
|
|
9
|
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
|
Clin Cancer Res
|
2006
|
2.20
|
|
10
|
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
|
J Urol
|
2008
|
1.95
|
|
11
|
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.
|
Front Biosci
|
2007
|
1.89
|
|
12
|
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
|
Clin Cancer Res
|
2008
|
1.87
|
|
13
|
Clinical safety of a viral vector based prostate cancer vaccine strategy.
|
J Urol
|
2007
|
1.84
|
|
14
|
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
|
Clin Cancer Res
|
2011
|
1.82
|
|
15
|
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
|
Clin Cancer Res
|
2008
|
1.81
|
|
16
|
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.
|
Oncologist
|
2010
|
1.72
|
|
17
|
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
|
Expert Opin Investig Drugs
|
2009
|
1.71
|
|
18
|
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
|
J Clin Oncol
|
2010
|
1.65
|
|
19
|
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
|
Clin Cancer Res
|
2008
|
1.60
|
|
20
|
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
|
J Urol
|
2005
|
1.59
|
|
21
|
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
|
Clin Cancer Res
|
2008
|
1.56
|
|
22
|
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
|
BJU Int
|
2013
|
1.47
|
|
23
|
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
|
BJU Int
|
2008
|
1.41
|
|
24
|
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.
|
Oncology (Williston Park)
|
2008
|
1.38
|
|
25
|
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
|
BJU Int
|
2009
|
1.37
|
|
26
|
Costimulatory molecules as adjuvants for immunotherapy.
|
Front Biosci
|
2006
|
1.37
|
|
27
|
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
|
Cancer Biol Ther
|
2006
|
1.33
|
|
28
|
A retrospective study of the time to clinical endpoints for advanced prostate cancer.
|
BJU Int
|
2005
|
1.33
|
|
29
|
An update on androgen deprivation therapy for prostate cancer.
|
Endocr Relat Cancer
|
2010
|
1.32
|
|
30
|
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.
|
Clin Cancer Res
|
2010
|
1.30
|
|
31
|
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.
|
Blood
|
2012
|
1.30
|
|
32
|
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
|
Cancer Invest
|
2009
|
1.23
|
|
33
|
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.
|
Cancer Immunol Immunother
|
2010
|
1.17
|
|
34
|
Paradigm shifts in cancer vaccine therapy.
|
Exp Biol Med (Maywood)
|
2008
|
1.13
|
|
35
|
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
|
Cancer Immunol Immunother
|
2014
|
1.13
|
|
36
|
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
|
J Clin Pharmacol
|
2009
|
1.11
|
|
37
|
Prostate cancer immunotherapy.
|
Clin Cancer Res
|
2011
|
1.11
|
|
38
|
Clinical evaluation of TRICOM vector therapeutic cancer vaccines.
|
Semin Oncol
|
2012
|
1.09
|
|
39
|
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
|
Crit Rev Immunol
|
2007
|
1.07
|
|
40
|
Combining radiation and immunotherapy for synergistic antitumor therapy.
|
Curr Opin Mol Ther
|
2009
|
1.03
|
|
41
|
A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229).
|
Clin Breast Cancer
|
2006
|
1.02
|
|
42
|
Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.
|
J Immunol
|
2013
|
1.01
|
|
43
|
Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.
|
Expert Opin Biol Ther
|
2010
|
0.99
|
|
44
|
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
|
Cancer Immunol Immunother
|
2013
|
0.98
|
|
45
|
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology.
|
J Nucl Med
|
2012
|
0.98
|
|
46
|
PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.
|
Expert Opin Biol Ther
|
2007
|
0.97
|
|
47
|
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.
|
Cancer Immunol Immunother
|
2011
|
0.97
|
|
48
|
Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
|
Clin Cancer Res
|
2005
|
0.96
|
|
49
|
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
|
BJU Int
|
2007
|
0.95
|
|
50
|
From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.
|
Expert Rev Vaccines
|
2011
|
0.94
|
|
51
|
Nivolumab: promising survival signal coupled with limited toxicity raises expectations.
|
J Clin Oncol
|
2014
|
0.94
|
|
52
|
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
|
J Urol
|
2009
|
0.93
|
|
53
|
Serum antibodies to blood group A predict survival on PROSTVAC-VF.
|
Clin Cancer Res
|
2013
|
0.92
|
|
54
|
Promising novel immunotherapies and combinations for prostate cancer.
|
Future Oncol
|
2009
|
0.91
|
|
55
|
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.
|
Proc Natl Acad Sci U S A
|
2014
|
0.91
|
|
56
|
IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy.
|
J Biomed Biotechnol
|
2010
|
0.90
|
|
57
|
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.
|
Cancer Immunol Immunother
|
2013
|
0.90
|
|
58
|
Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide.
|
Am J Ther
|
2003
|
0.90
|
|
59
|
PSA-based vaccines for the treatment of prostate cancer.
|
Expert Rev Vaccines
|
2006
|
0.88
|
|
60
|
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
|
Cancer Immunol Immunother
|
2009
|
0.88
|
|
61
|
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.
|
Clin Lung Cancer
|
2010
|
0.88
|
|
62
|
Poxviral vectors for cancer immunotherapy.
|
Expert Opin Biol Ther
|
2012
|
0.88
|
|
63
|
The role of soluble CD40L in immunosuppression.
|
Oncoimmunology
|
2013
|
0.88
|
|
64
|
TRICOM vector based cancer vaccines.
|
Curr Pharm Des
|
2006
|
0.87
|
|
65
|
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
|
J Urol
|
2010
|
0.86
|
|
66
|
Therapeutic vaccines for prostate cancer.
|
Oncologist
|
2006
|
0.86
|
|
67
|
Vaccines as monotherapy and in combination therapy for prostate cancer.
|
Clin Transl Sci
|
2010
|
0.85
|
|
68
|
Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy.
|
J Immunol
|
2014
|
0.85
|
|
69
|
Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
|
Clin Genitourin Cancer
|
2007
|
0.85
|
|
70
|
Hepcidin, anaemia, and prostate cancer.
|
BJU Int
|
2011
|
0.85
|
|
71
|
The use of bisphosphonates in cancer patients.
|
Acta Oncol
|
2007
|
0.85
|
|
72
|
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
|
Cancer J
|
2013
|
0.84
|
|
73
|
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer.
|
Int J Cancer
|
2013
|
0.84
|
|
74
|
Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4).
|
Int J Cancer
|
2007
|
0.84
|
|
75
|
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
|
J Natl Cancer Inst
|
2012
|
0.83
|
|
76
|
Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.
|
J Natl Compr Canc Netw
|
2012
|
0.83
|
|
77
|
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
|
Clin Prostate Cancer
|
2004
|
0.83
|
|
78
|
The current and emerging role of immunotherapy in prostate cancer.
|
Clin Genitourin Cancer
|
2010
|
0.83
|
|
79
|
Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway.
|
Am J Ther
|
2010
|
0.82
|
|
80
|
Combining Vaccines with Conventional Therapies for Cancer.
|
Update Cancer Ther
|
2007
|
0.82
|
|
81
|
Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
|
Expert Rev Vaccines
|
2003
|
0.81
|
|
82
|
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity.
|
Oncoimmunology
|
2012
|
0.81
|
|
83
|
Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.
|
Vaccine
|
2011
|
0.81
|
|
84
|
Novel therapeutic strategies in prostate cancer.
|
Cancer Biol Ther
|
2004
|
0.81
|
|
85
|
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.
|
Expert Rev Vaccines
|
2011
|
0.80
|
|
86
|
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.
|
Oncologist
|
2013
|
0.79
|
|
87
|
Ipilimumab in prostate cancer.
|
Expert Opin Biol Ther
|
2012
|
0.79
|
|
88
|
Immunotherapy for prostate cancer: what's the future?
|
Hematol Oncol Clin North Am
|
2006
|
0.79
|
|
89
|
Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
|
BJU Int
|
2006
|
0.79
|
|
90
|
Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine.
|
Clin Genitourin Cancer
|
2011
|
0.78
|
|
91
|
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
|
Clin Genitourin Cancer
|
2013
|
0.78
|
|
92
|
Cancer vaccines: current directions and perspectives in prostate cancer.
|
Curr Opin Mol Ther
|
2009
|
0.78
|
|
93
|
Therapeutic vaccines for prostate cancer: a review of clinical data.
|
Curr Opin Investig Drugs
|
2005
|
0.77
|
|
94
|
Therapeutic prostate cancer vaccines: a review of the latest developments.
|
Curr Opin Investig Drugs
|
2008
|
0.77
|
|
95
|
A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local definitive therapy.
|
Clin Genitourin Cancer
|
2006
|
0.77
|
|
96
|
Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer.
|
Rev Urol
|
2003
|
0.77
|
|
97
|
A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.
|
J Immunol Methods
|
2003
|
0.77
|
|
98
|
Immunologic monitoring of cellular immune responses in cancer vaccine therapy.
|
J Biomed Biotechnol
|
2011
|
0.76
|
|
99
|
A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors.
|
Clin Colorectal Cancer
|
2006
|
0.75
|
|
100
|
Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.
|
Future Oncol
|
2005
|
0.75
|
|
101
|
Current perspectives in prostate cancer vaccines.
|
Anticancer Agents Med Chem
|
2009
|
0.75
|
|
102
|
Early treatment gets the benefit.
|
J Clin Oncol
|
2006
|
0.75
|
|
103
|
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
|
Immunotherapy
|
2011
|
0.75
|
|
104
|
Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer.
|
Asian J Androl
|
2011
|
0.75
|
|
105
|
Prostate cancer: Intermediate efficacy end points to assess modern therapies.
|
Nat Rev Urol
|
2013
|
0.75
|
|
106
|
Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.
|
Cancers (Basel)
|
2012
|
0.75
|
|
107
|
Even more cost savings?
|
J Oncol Pract
|
2006
|
0.75
|
|
108
|
Adding fuel to the fire: immunogenic intensification.
|
Hum Vaccin Immunother
|
2014
|
0.75
|
|
109
|
Immunotherapy in genitourinary malignancies.
|
Curr Opin Urol
|
2016
|
0.75
|
|
110
|
Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature.
|
Am J Ther
|
2007
|
0.75
|
|
111
|
Prostate cancer immunotherapy: the path forward.
|
Curr Opin Support Palliat Care
|
2017
|
0.75
|
|
112
|
Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy.
|
Am J Ther
|
2005
|
0.75
|
|
113
|
The evolving role of immunotherapy in prostate cancer.
|
Curr Opin Oncol
|
2016
|
0.75
|
|
114
|
Dramatic and prolonged PSA response after retreatment with a PSA vaccine.
|
Clin Genitourin Cancer
|
2013
|
0.75
|
|
115
|
Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.
|
Int J Cancer
|
2014
|
0.75
|
|
116
|
Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scans.
|
Am J Ther
|
2004
|
0.75
|